The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Irwin was the first to observe that if the size of the plastic zone around a crack is small compared to the size of the crack, the energy required to grow the crack will not be critically dependent on the state of stress (the plastic zone) at the crack tip. In other words, a purely elastic solution may be used to calculate the amount of energy available for fracture. The energy release rate for crack growth or strain energy release rate may then be calculated as the change in elastic strain energy per unit area of crack growth, i.e.,
First, the species is compatible with the main wine yeast Saccharomyces cerevisiae, though in cases where both MLF and alcoholic fermentation are started together, the yeast most often outcompetes the bacterium for nutritional resources which may cause a delay in the onset of malolactic fermentation. Second, most strains of O. oeni are tolerant to the low pH levels of wine and can usually deal with the standard alcohol levels that most wines reach by the end of fermentation. Additionally, while sulfur dioxide levels above 0.8 molecular SO2 (pH dependent but roughly 35-50 ppm) will inhibit the bacteria, O. oeni is relatively resistant compared to other LAB. Finally, O. oeni tends to produce the least amount of biogenic amines (and most lactic acid) among the lactic acid bacteria encountered in winemaking.
=== Bibliography === Edwards, Giles; Isaby, Jonathan (2008). Boris v. Ken: How Boris Johnson Won London. London: Politico's. ISBN 978-1-84275-225-8. Gimson, Andrew (2012). Boris: The Rise of Boris Johnson (2nd ed.). Simon & Schuster. Nekov, Momchil (2013). От първо лице (1st ed.). Sofia: Ciela. ISBN 978-954-28143-3-7. Purnell, Sonia (2011). Just Boris: Boris Johnson: The Irresistible Rise of a Political Celebrity. London: Aurum Press Ltd. ISBN 978-1-84513-665-9.
Sources: en.wikipedia.org
Dayhoff died of a heart attack at the age of 57 on February 5, 1983. A fund was established after her death in 1984 to endow the Margaret O. Dayhoff Award, one of the top national honors in biophysics. The award is presented to a woman who "holds very high promise or has achieved prominence while developing the early stages of a career in biophysical research within the purview and interest of the Biophysical Society." It is presented at the annual meeting of the Biophysical Society and includes an honorarium of $2,000. She was survived by her husband, Edward S. Dayhoff of Silver Spring; two daughters, Ruth E. Dayhoff Brannigan of College Park, and Judith E. Dayhoff of Silver Spring, and her father, Kenneth W. Oakley of Silver Spring.
If the incircle is tangent to the sides AB, BC, CD, DA at T1, T2, T3, T4 respectively, and if N1, N2, N3, N4 are the isotomic conjugates of these points with respect to the corresponding sides (that is, AT1 = BN1 and so on), then the Nagel point of the tangential quadrilateral is defined as the intersection of the lines N1N3 and N2N4. Both of these lines divide the perimeter of the quadrilateral into two equal parts. More importantly, the Nagel point N, the "area centroid" G, and the incenter I are collinear in this order, and NG = 2GI. This line is called the Nagel line of a tangential quadrilateral. In a tangential quadrilateral ABCD with incenter I and where the diagonals intersect at P, let HX, HY, HZ, HW be the orthocenters of triangles AIB, BIC, CID, DIA. Then the points P, HX, HY, HZ, HW are collinear.
=== Excitotoxicity and glutamate receptors === Excitotoxicity is phenomenon in which glutamate receptors are inappropriately activated. It can be caused by prolonged excitatory synaptic transmission in which high levels of glutamate neurotransmitter cause excessive activation in a postsynaptic neuron that can result in the death of the postsynaptic neuron. Following brain injury (such as from ischemia), it has been found that excitotoxicity is a significant cause of neuronal damage. This can be understandable in the case where sudden perfusion of blood after reduced blood flow to the brain can result in excessive synaptic activity caused by the presence of increased glutamate and aspartate during the period of ischemia.
Sources: en.wikipedia.org
== Philosophical background == Traditional Chinese medicine includes a broad range of practices sharing common concepts that developed in China for more than 2,000 years, including various forms of herbal medicine, acupuncture, massage (tui na), exercise (qigong), and dietary therapy. It is primarily used as a complementary alternative medicine approach. Traditional practices are widely used in China and, in an adapted form, also in the West. Its philosophy is based on School of Yin Yang, which incorporates Five Phases theory and Yin–Yang theory, and elements of which were absorbed by Daoism. Philosophical texts influenced medical thought and practice, mostly by being grounded in the same theories of qi, yin-yang and wuxing and microcosm-macrocosm analogies.
Christianity, bolstered by Constantine's support, began shaping all aspects of life in the early Byzantine Empire. Despite the transition, the historian Anthony Kaldellis views Christianity as "bringing no economic, social, or political changes to the state other than being more deeply integrated into it". When the Roman state in the West collapsed politically, cultural differences began to divide the Christian churches of the East and West. Internal disputes within the Eastern churches led to the migration of monastic communities to Rome, exacerbating tensions between Rome and Constantinople. These disputes, particularly in Egypt and the eastern Mediterranean, eventually split the church into three branches: Chalcedonian, Monophysite (Coptic), and Nestorian. The Chalcedonian group maintained dominance within the empire's territories, while the Monophysite and Nestorian branches largely fell under Muslim rule in the 7th century. Eastern patriarchs frequently sought the Papacy's mediation in doctrinal and practical matters, but the pope's authority was not universally acknowledged, even in nearby regions like Northern Italy. By 600, the Slavic settlement of the Balkans disrupted communication between Rome and Constantinople, further widening the divide. The Arab and Lombard invasions, and the increased Frankish presence, deepened this estrangement and intensified disputes over jurisdiction and authority between the two spiritual centres.
The gross (macroscopic) appearance of the brain in Alzheimer's disease is variable. In many cases the cortical sulci are widened and the gyri are shrunken, but the degree of cortical atrophy varies. It can sometimes be difficult to discern, particularly in the very elderly. The areas most affected by atrophy are the medial temporal lobe including the hippocampal formation, the amygdala, the frontal lobe and the parietal lobe; the occipital lobe is relatively unaffected by atrophy. The volume of the ventricles increases in parallel with cortical shrinkage. Studies using MRI and PET have documented reductions in the size of specific brain regions in people with Alzheimer's disease as they progress from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults. These macroscopic changes in the brain are not specific to Alzheimer's and can occur in other disorders and to some extent in normal aging. At the microscopic level, the defining histopathologic characteristics of Alzheimer's disease are abundant amyloid plaques and neurofibrillary tangles in certain brain regions. Both of these abnormalities are clearly visible by microscopy, and amyloid imaging. In the early stages of disease, tangles are present mainly in the medial temporal lobe and plaques are present mainly in the neocortex, but as the disease progresses the lesions proliferate throughout much of the brain.
==== Due to use of medication ==== Urine tests can be falsely positive in those that are taking the medications: chlorpromazine, promethazine, phenothiazines, methadone, aspirin, carbamazepine and drugs that cause high urinary pH.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.